logo-loader
viewPropanc Biopharma, Inc.

Propanc Biopharma boosts its patent portfolio for its anti-cancer therapy

Propanc Biopharma Inc (OTCMTKS:PPCBD) CEO James Nathanielsz tells Proactive Investors the company has boosted its intellectual property portfolio for its anti-cancer technology currently in development.

The biopharmaceutical company’s portfolio now has 65 patents either in force or pending in most major countries around the globe. Nathanielsz also updated investors on the reasoning behind the company's recent reverse stock split.

Quick facts: Propanc Biopharma, Inc.

Price: 0.155 USD

OTCQB:PPCB
Market: OTCQB
Market Cap: $203.29 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

2 hours, 41 minutes ago

2 min read